Journals / Aydın Sağlık Dergisi / 2020 / Cilt: 6 - Sayı: 2

A New Candidate Biomarker in Peripheral Blood of Patients with Metastatic Lung Cancer: High DICER1 Expression Level

Metastatik Akciğer Kanserli Hastaların Periferik Kanında Yeni Aday Biyomarker: Yüksek DICER1 Ekspresyon Düzeyi

Pages
123–138
Publication Date
2020-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The expression level of DICER1 gene in the peripheral blood lymphocytes of patients with metastatic lung cancer was increased by 1.756 (2-ΔΔCt) fold compared to the healthy control group and the increased expression level was statistically significant, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Lung cancer is in the first place in the world in terms of cancerrelated incidence and mortality.
📊
Key Findings & Data:DICER1 has an important function in microRNA biogenesis.
💡
Conclusion & Impact:Results: The expression level of DICER1 gene in the peripheral blood lymphocytes of patients with metastatic lung cancer was increased by 1.756 (2-ΔΔCt) fold compared to the healthy control group and the increased expression level was statistically significant, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akciğer kanseri · DICER1 · Metastaz

Abstract

Objective: Lung cancer is in the first place in the world in terms of cancerrelated incidence and mortality. Since cancer is a multifactorial disease, it is very important to try to illuminate the mechanisms associated with cancer. It is known that miRNA activity, which is closely related to carcinogenesis, is impaired with various mechanisms. One of these mechanisms is the molecular changes that occur during miRNA process. DICER1 has an important function in microRNA biogenesis. In our study, it was aimed to investigate the effect of DICER1 gene expression level on metastatic lung cancer development. Material and Method: The study groups consist of peripheral blood samples of 47 patients with metastatic lung cancer who had recently been diagnosed but had never been treated and 45 healthy people. The investigated DICER1 target gene was examined simultaneously with the HPRT1 reference gene by using the Real-Time PCR method. The results of DICER1 gene expression levels of patients and those of healthy individuals were compared. The results were evaluated by using the 2-ΔΔCT method. Results: The expression level of DICER1 gene in the peripheral blood lymphocytes of patients with metastatic lung cancer was increased by 1.756 (2-ΔΔCt) fold compared to the healthy control group and the increased expression level was statistically significant, p

Özet

Amaç: Akciğer kanseri, dünyada kansere bağlı insidans ve mortalite açısından birinci sırada yer almaktadır. Kanserin multifaktoriyel bir hastalık olması nedeniyle kanserle ilişkili mekanizmaların aydınlatılmaya çalışılması oldukça önem taşımaktadır. Kanserle yakından ilgili olan miRNA aktivitesinin çeşitli mekanizmalarla bozulduğu bilinmektedir. Bu mekanizmalardan biri de miRNA işlenmesi sırasında meydana gelen moleküler değişikliklerdir. DICER1, microRNA biyogenezinde önemli bir yere sahiptir. Çalışmamızda, akciğer kanserli hastaların periferik kan lenfositlerinde DICER1 gen ifade düzeyinin sağlıklı kişilerle karşılaştırılarak metastatik akciğer kanseri gelişimindeki etkisinin araştırılması amaçlanmıştır. Materyal ve Metot: Çalışma grubu yeni tanı almış ve daha önce hiç tedavi görmemiş 47 akciğer kanserli hasta ile 45 sağlıklı kişinin periferik kan örneklerinden oluşturuldu. Araştırılan DICER1 hedef geni, HPRT1 referans geni ile eş zamanlı olarak Gerçek-Zamanlı PCR yöntemiyle incelendi. Akciğer kanser hastalarına ait gen ekspresyon düzeyi ile sağlıklı kişilerden oluşan kontrol grubu DICER1 gen ekspresyon sonuçları karşılaştırıldı. Sonuçlar 2-ΔΔCT metodu kullanılarak değerlendirildi. Sonuçlar: Akciğer kanser hastalarının periferik kan lenfositlerinde DICER1 gen ifade düzeyinin (2-ΔΔCt) kontrol grubuna göre 1,756 kat arttığı, bu artmış ekspresyon düzeyinin istatistiksel açıdan anlamlı (p

🔖

Cite This Article

SARAL, M. A., ÇIRAK, N., TÜRKCAN, G., ÖDEMİŞ, D. A., TUNÇER, Ş. B., ERCİYAS, S. K., ERDOĞAN, Ö. Ş., TAMBAŞ, M., YAZICI, H. (2020). A New Candidate Biomarker in Peripheral Blood of Patients with Metastatic Lung Cancer: High DICER1 Expression Level. Aydın Sağlık Dergisi, Cilt: 6 - Sayı: 2, 123–138. https://ajindex.com/articles/738538

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Alberg, A. J., Ford, J. G., Samet, J. M., & American College of Chest, P. (2007). Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 29S-55S. doi: 10.1378/chest.07-1347 [2] Bade, B. C., & Dela Cruz, C. S. (2020). Lung Cancer 2020:
  2. Epidemiology, Etiology, and Prevention. Clin Chest Med, 41(1), 1-24. doi: 10.1016/j.ccm.2019.10.001 [3] Boeri, M., Pastorino, U., & Sozzi, G. (2012). Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J, 18(3), 268-274. doi: 10.1097/PPO.0b013e318258b743 [4] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6), 394-424. doi: 10.3322/caac.21492 [5] Cagle, P. T., Allen, T. C., & Olsen, R. J. (2013). Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med, 137(9), 1191-1198. doi: 10.5858/arpa.2013-0319-CR [6] Chatziandreou, I., Tsioli, P., Sakellariou, S., Mourkioti, I., Giannopoulou, I., Levidou, G.,. Saetta, A. A. (2015). Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. PLoS One, 10(7), e0133859. doi: 10.1371/journal.pone.0133859 [7] Chen, X., Li, W. F., Wu, X., Zhang, H. C., Chen, L., Zhang, P. Y.,. Tang, K. F. (2017). Dicer regulates non-homologous end joining and is associated with chemosensitivity in colon cancer patients. Carcinogenesis, 38(9), 873-882. doi: 10.1093/carcin/bgx059 [8] Cheng, L., Alexander, R. E., Maclennan, G. T., Cummings, O. W., Montironi, R., Lopez-Beltran, A.,. Zhang, S. (2012). Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol, 25(3), 347-369. doi: 10.1038/modpathol.2011.215 [9] Chiosea, S., Jelezcova, E., Chandran, U., Acquafondata, M., McHale, T., Sobol, R. W., & Dhir, R. (2006). Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol, 169(5), 1812-1820. doi: 10.2353/ajpath.2006.060480 [10] Chiosea, S., Jelezcova, E., Chandran, U., Luo, J., Mantha, G., Sobol, R. W., & Dacic, S. (2007). Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res, 67(5), 2345-2350. doi: 10.1158/0008- 5472.CAN-06-3533 [11] Del Vescovo, V., & Denti, M. A. (2015). microRNA and Lung Cancer. Adv Exp Med Biol, 889, 153-177. doi: 10.1007/978-3-319-23730-5_9 [12] Erson, A. E., & Petty, E. M. (20